TECENTRIQ + Nab Paclitaxel
Keeping patients with TNBC connected to life
IMpassion 130 is the first positive Phase 3 trial for a cancer immunotherapy combination in first-line metastatic TNBC.1
Advanced TNBC is an aggressive breast cancer with poor prognosis
Unresectable locally advanced or metastatic triple-negative (hormone-receptor–negative and human epidermal growth factor receptor 2 [HER2]–negative) breast cancer (TNBC) is an aggressive disease, which has been associated with poor outcomes.1
TECENTRIQ: FIRST CANCER
AVAILABLE IN EUROPE FOR TNBC1
A paradigm shift in first-line advanced TNBC. The first cancer immunotherapy combination to extend survival in PD-L1+ advanced TNBC.
TECENTRIQ in combination with nab-paclitaxel (nab-pac) is indicated for the treatment of adult patients with unresectable locally advanced or metastatic TNBC whose tumours have PD-L1 expression ≥1% and who have not received prior chemotherapy for metastatic disease.2
IMpassion130: A robust Phase 3 efficacy trial evaluating TECENTRIQ + nab-pac in advanced TNBC3
A Phase 3 trial of 902 patients with metastatic triple-negative breast cancer receiving atezolizumab plus nab-pac or placebo nab-pac.3 Primary end points progression-free survival (in the intention-to-treat population and PD-L1+subgroup) and OS. Treatment continued until disease progression or an unacceptable level of toxic effects occurred. Patients were stratified by prior neoadjuvant or adjuvant taxane therapy, liver metastases at baseline, and PD-L1 expression.
41% of patients in IMpassion130 had PD-L1+ disease, defined as ≥1% expression on IC using the Ventana SP142 assay.3
A new standard of extended survival in patients with PD-L1+ advanced TNBC1
Expression of PD-L1 ≥1% in tumour infiltrating IC was predictive of benefit in patients undergoing treatment with TECENTRIQ in combination with nab-pac3*
Median OS in patients with PD-L1+ TNBC was 25.0 months (95% CI: 19.6, 30.7) with TECENTRIQ plus nab-pac vs 18.0 months (95% CI: 13.6, 20.1) with placebo plus nab-pac (stratified HR=0.71; 95% CI: 0.54, 0.94).3
What this means for patients with TNBC
Testing TNBC patients for PD-L1 status with the SP142 assay (IC≥1%) at metastatic diagnosis will help you select patients for TECENTRIQ in combination with nab-paclitaxel and improve first-line outcomes.
References & Notes
References & Notes
1 Schmid P, et al; IMpassion130 Trial Investigators. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med. 2018;379:2108–21.
2 TECENTRIQ (atezolizumab), Summary of Product Characteristics. 27 March 2020. Available from: https://www.medicines.org.uk/ (Accessed April 2020).
3 Schmid P, et al. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2020;21:44–59.